J. David Owens
President & CEO
Mr. Owens brings over 35 years of pharmaceutical and biotechnology management and commercialization experience. Mr. Owens was formerly the Co-CEO/President of OrthogenRx where he led the company to exit through acquisition by Avanos in 2022. Mr. Owens also served as Chief Business Officer for Novira Therapeutics, Inc., a privately held antiviral drug discovery company where he co-led a syndicated angel investment and then a Series A financing prior to the company's acquisition by Johnson & Johnson. Previously, Mr. Owens held executive positions as Senior Vice President, and Business Unit Head of the Surgical Products Division at King Pharmaceuticals (now part of Pfizer) and as Vice President of Global Marketing & Medical Affairs at Aventis Pharma (now part of Sanofi). Earlier in his career, Mr. Owens held commercial operations roles at Genentech, Merck, and Abbott Labs. Mr. Owens is a graduate of the University of Wisconsin, School of Pharmacy. Mr. Owens is also a General Partner with Bowmans Tower Venture Partners, an early-stage/seed level investment group.
Rob Gensure, MD, PhD
Chief Medical Officer
Dr. Rob Gensure joined BiologicsMD as Chief Medical Officer in 2009. He is one of the inventors of the technology and is Chief of Pediatric Endocrinology at Tufts University School of Medicine in Boston. He is board certified in pediatric endocrinology and pediatrics. Dr. Gensure graduated from Tulane University School of Medicine and completed his residency at Massachusetts General Hospital.
Robyn Goforth, PhD
Chief Scientific Officer
Dr. Robyn Goforth joined BiologicsMD as Chief Scientific Officer in 2009. She has over 15 years experience in functional protein design and protein production. She has published over a dozen scientific papers in the fields of biochemistry and bioengineering. Dr. Goforth has also been principal investigator and co-principal investigator on over $10MM in National Institute of Health, Department of Energy, and Small Business Innovation Research grants. She was named in June 2011 one of the top 40 business leaders under 40 by the Arkansas Business Journal.
Frank Gallagi
Chief Financial Officer
Mr. Gallagi joined BiologicsMD in 2020, bringing over 15 years of drug discovery, medical device, and specialty ingredient senior management experience to the team. In addition he is a long-time venture capital investor and a Founding Partner of Bowman’s Tower Venture Partners. Prior positions include Chief Financial Officer of OrthogenRx (sold to Avanos in 2022), and managing partner at various boutique venture capital firms since 2005, having begun his career at KPMG. Frank graduated with a B.S. in Accounting from Fordham University, and is a Certified Public Accountant.